True North, a private equity firm, agreed to acquire an 8% stake in Anthem Biosciences, a pharmaceutical company. Financial terms were not disclosed. "Our investment in Anthem Biosciences reflects our commitment to drive growth in the healthcare and pharmaceuticals area in the country. Anthem has scripted an impressive story since inception and has a strong, competitive positioning with an attractive product pipeline and long-standing relationships with its customers. We are looking forward to an exciting partnership with the team," Satish Chander, True North Partner.